Understanding the relationship between hyperglycemia, BMI-1, PTEN, and PHLPP functions, may contribute in the future to the development of therapeutic approaches that will be better adapted to the molecular context and the specificity of endometrial cancers and more effective in cases of metabolic diseases co-existence. This evidence concerns the gene PHLPP1 and endometrial cancer.